Stock Analysis
Spyre Therapeutics, Inc. (SYRE) Stock Analysis
Spyre Therapeutics, Inc. (SYRE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Spyre Therapeutics, Inc. (SYRE) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 81/100. Value is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SYRE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $104.00 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $9.19B |
| P/E Ratio (TTM) | -37.96 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.94 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.69 |
| Volume | 746.24K |
| 52-week range | $22.13-$110.64 |
| RSI 14 | 59.4 |
| 50-Day SMA | $91.48 |
| 200-Day SMA | $76.67 |
| Analyst Price Target | $122.83 |
| Next Earnings | Feb 18, 2027 |
SYRESpyre Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum81
- Value44
- Quality61
- Risk resilience53
- Sentiment—
SYRE Stock Analysis Summary
Spyre Therapeutics, Inc. (SYRE) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 81/100. Value is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, SYRE has AIQ Score of 64/100 with Momentum base of 81/100 and fading Value at 44/100. Wait for component alignment before adding exposure.
Momentum (81/100) leads while Value (44/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.06% stock move · SYRE classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SYRE Bullish or Bearish Right Now?
SYRE currently has a neutral overall setup. Momentum is the strongest factor at 81/100, while Value is weakest at 44/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 81/100.
- - Price is +13.68% above its 50-day SMA.
- - Analyst target implies +18.11% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (34 vs 3).
- - Value is the current constraint at 44/100.
Current Consensus
SYRE's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 9 neutral, and 3 sell votes. SYRE's 14-day RSI is 59.4, which places the stock in a constructive momentum range. SYRE's beta is 1.69, indicating greater market sensitivity than the broad market.
What Changed in SYRE?
The largest recent change in SYRE is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the SYRE Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SYRE Decision Framework
Public evidence layers, setup checks, and risk context for Spyre Therapeutics, Inc..
Spyre Therapeutics, Inc. (SYRE) Stock Analysis
Spyre Therapeutics, Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 81/100. Beta is 1.69, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SYRE is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that momentum leads at 81/100 while value lags at 44/100. |
| Factor Evidence | Momentum 81/100 · Value 44/100 · Quality 61/100 · Risk 53/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 81/100.
Momentum is 81/100 and RSI (14) is 59.4.
SYRE is in a Neutral regime at 64/100.
Risk factor is 53/100 with beta 1.69 and annual volatility 66.66%.
Current conflict: momentum leads at 81/100 while value lags at 44/100.
SYRE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SYRE Fundamentals
SYRE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SYRE Technical Analysis
SYRE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SYRE Stock Catalysts
Track SYRE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SYRE Dividend Analysis
SYRE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SYRE Financial Data
SYRE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SYRE Risk Analysis
SYRE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SYRE Stock News
SYRE stock news, market tone, recent headlines, and catalyst context.
SYRE vs Biotechnology Peers
Current peer cohort: SYRE · TARS · TGTX · TNGX · TRVI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SYRE Current stock | 64/100 | 44/100 | 81/100 | 53/100 | 2.57 | 66.66% | Current |
| TARS Tarsus Pharmaceuticals, Inc. | 65/100 | 75/100 | 76/100 | 59/100 | 0.36 | 45.02% | SYRE vs TARS |
| TGTX TG Therapeutics, Inc. | 76/100 | 65/100 | 93/100 | 63/100 | 1.74 | 46.06% | SYRE vs TGTX |
| TNGX Tango Therapeutics, Inc. | 61/100 | — | 60/100 | 38/100 | 1.61 | 101.07% | SYRE vs TNGX |
| TRVI Trevi Therapeutics, Inc. | 63/100 | — | 52/100 | 51/100 | 0.52 | 59.27% | SYRE vs TRVI |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for SYRE: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SYRE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SYRE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SYRE Stock FAQ
What is SYRE stock price today?
Spyre Therapeutics, Inc.'s current stock price is $104.00. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SYRE bullish or bearish right now?
SYRE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SYRE's market cap?
SYRE's market cap is $9.19B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SYRE's current P/E ratio?
SYRE's current P/E ratio is -37.96 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SYRE's RSI?
SYRE's 14-day RSI is 59.4 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SYRE above its 50-day and 200-day moving averages?
SYRE is 13.68% from its 50-day SMA and 35.65% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SYRE's next earnings date?
SYRE's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SYRE pay a dividend?
SYRE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.